Paclitaxel, carboplatin and hexamethylmelanine (TAXCHEX) as first-line therapy for ovarian cancer

被引：0

作者：

Hartenbach, E ^{[1
]}

Harris, L ^{[1
]}

Bailey, H ^{[1
]}

Grosen, E ^{[1
]}

Larrison, E ^{[1
]}

Chen, D ^{[1
]}

Twiggs, L ^{[1
]}

Schink, J ^{[1
]}

机构：

[1] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI 53706 USA

来源：

7TH BIENNIAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY | 1999年

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We have conducted a pilot study to evaluate the safety and efficacy of adding hexamethylmelamine to the popular ovarian cancer regimen of paclitaxel plus carboplatin. The response rate was 76%. Toxicity was acceptable. Qualify of life showed improvement over the course of therapy. The addition of hexamethylmelamine to paclitaxel and carboplatin is a well-tolerated multi-drug combination for women with advanced ovarian cancer that deserves further testing in a phase III setting.

引用

页码：211 / 214

页数：4

共 10 条

[1] [Anonymous], 1995, JAMA, V273, P491
[2] CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION
CALVERT, AH
NEWELL, DR
GUMBRELL, LA
OREILLY, S
BURNELL, M
BOXALL, FE
SIDDIK, ZH
JUDSON, IR
GORE, ME
WILTSHAW, E
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) : 1748 - 1756
[3] PHASE-II STUDY AND LONG-TERM FOLLOW-UP OF PATIENTS TREATED WITH TAXOL FOR ADVANCED OVARIAN ADENOCARCINOMA
EINZIG, AI
WIERNIK, PH
SASLOFF, J
RUNOWICZ, CD
GOLDBERG, GL
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (11) : 1748 - 1753
[4] CREATININE CLEARANCE - BEDSIDE ESTIMATE
JELLIFFE, RW
[J]. ANNALS OF INTERNAL MEDICINE, 1973, 79 (04) : 604 - 605
[5] TAXOL - A UNIQUE ANTINEOPLASTIC AGENT WITH SIGNIFICANT ACTIVITY IN ADVANCED OVARIAN EPITHELIAL NEOPLASMS
MCGUIRE, WP
ROWINSKY, EK
ROSENSHEIN, NB
GRUMBINE, FC
ETTINGER, DS
ARMSTRONG, DK
DONEHOWER, RC
[J]. ANNALS OF INTERNAL MEDICINE, 1989, 111 (04) : 273 - 279
[6] McGuire WP, 1998, SEMIN ONCOL, V25, P340
[7] Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
McGuire, WP
Hoskins, WJ
Brady, MF
Kucera, PR
Partridge, EE
Look, KY
ClarkePearson, DL
Davidson, M
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) : 1 - 6
[8] OZOLS RF, 1997, SEM ONCOL S2, V24
[9] OZOLS RF, 1997, SEM ONCOL S15, V24
[10] Thigpen T, 1995, SEMIN ONCOL, V22, P23

← 1 →